Gaming and Abuse of Orphan Drugs

Pattern of gaming the system by slicing and dicing indications so that drugs qualify for lucrative orphan status benefits and getting taxpayer subsidies for blockbuster drugs, says a veteran scientist in USA. Companies are intentionally exploiting the law by putting up an initial listing of only single narrow indication for an orphan drugs use, which is just enough to qualify for "orphan" drug designation. Under the terms of this act, companies can receive federal taxpayer subsidies of up to half a million dollars a year for up to four years per drug, large tax credits and waivers of marketing application fees that can cost more than $2 million. In addition, the Food and Drug Administration (FDA) can grant companies seven years of marketing exclusivity for an orphan drug to ensure they recoup the costs of research and development. When those financial incentives become sort of an investment opportunity to take advantage of the Orphan Drug Act. The review found that orphan drug spending in the United States totalled $15 billion in 2007 and $30 billion in 2013, an increase from 4.8 percent of total pharmaceutical spending to 8.9 percent. The current study projects orphan drug spending will remain fairly stable as a proportion of total drug spending. That stands in contrast to other published reports that estimate orphan drugs will account for 20 percent of worldwide spending on drugs (other than generics) by 2020.

  • Financial incentives
  • Recouping the costs of research and development for orphan drugs
  • Forecasts of amount to be spent on orphan drugs by 2020

Related Conference of Gaming and Abuse of Orphan Drugs

October 18-19, 2017

6th Global Congress on Mass Spectrometry

Osaka, Japan
October 19-20, 2017

9th Annual Congress on Drug Design & Drug Formulation

Seoul, South Korea
October 19-20, 2017

4th International Conference and Exhibition on Pain Medicine

(10 Plenary Forums - 1 Event)
San Francisco, California, USA
October 30-November 01, 2017
A B2B Networking & Global Knowledge Exchange Forum

Annual Congress on Emerging Orphan Drugs and  Rare Diseases

San Antonio, Texas, USA
April 20-21, 2018

4th International Conference on Antibiotics: R&D, B2B

Las Vegas, Nevada, USA
April 26-27, 2018

11th European Biosimilars Congress

Rome, Italy
May 07-09, 2018

15th Annual European Pharma Congress

Frankfurt, Germany
June 18-19, 2018

9th Global Experts Meeting on Neuropharmacology

Paris, France
June 20-22, 2018

7th World Congress on Mass Spectrometry

Rome, Italy
July 09-10, 2018

12th Global
Pharmacovigilance & Clinical Trials Summit

Sydney, Australia
July 16-18, 2018

5th World Congress on Green Chemistry and Green Engineering

Melbourne, Australia
July 16-18, 2018

15th Asia-Pacific Pharma Congress

Melbourne, Australia
Jul 30-Aug 01, 2018

10th World Congress on Pharmacology

Barcelona, Spain
September 13-14, 2018

8th World Congress on Chromatography

Prague, Czech Republic
September 24-25, 2018

7th International Conference on Clinical Trials

Chicago, USA
(10 Plenary Forums - 1 Event)
October 22-23, 2018

18th Annual Pharma Middle East Congress

Abu Dhabi, UAE
November 05-06, 2018

18th Annual Pharmaceutical Chemical Analysis Congress

Madrid, Spain

Gaming and Abuse of Orphan Drugs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in